Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC).

@article{Molina2011PhaseIT,
  title={Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC).},
  author={Ana Maria Molina and Darren R Feldman and Michelle S. Ginsberg and Patricia M Fischer and Michael J Trinos and Sujata M. Patil and Robert J Motzer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 7_suppl},
  pages={311}
}
311 Background: Sunitinib a targeted tyrosine kinase inhibitor and everolimus an mTOR inhibitor both inhibit hypoxia-induced factor-dependent signaling and have activity in advanced renal cell carcinoma (RCC). The safety and maximum tolerated dose (MTD) of sunitinib in combination with everolimus was assessed in this phase I trial. METHODS Cohorts of 3-6 patients with mRCC received sunitinib at 37.5 or 50 mg daily for 4 weeks followed by 2 weeks off with everolimus administered either daily… CONTINUE READING
1 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…